Insight

Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe

Photo from Kamran Ahmed/X

Aug 29, 2024, 16:48

Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe

JAMA Oncology shared a post on X about a recent paper by Kamran Ahmed et al. published in JAMA Oncology.

“Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial”

Authors: Kamran Ahmed, Priya Kumthekar, Yolanda Pina, Youngchul Kim, Michael Vogelbaum, Hyo Han, Peter Forsyth

“Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging.”

Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers at the National Cancer Centre Singapore, shared this post, adding:

“Fascinating! With promising results for this group of very poor players.”

Source: JAMA Oncology/X and Melvin Chua/X

cancer HER2+ breast leptomeningeal disease Hyo Han JAMA Oncology Kamran Ahmed Melvin Chua Michael Vogelbaum National Cancer Centre Singapore OncoDaily Oncology pertuzumab Peter Forsyth Priya Kumthekar radiation therapy trastuzumab Yolanda Pina Youngchul Kim

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology